

The Right Therapy Starts with the Right Test: Novel Therapeutic Approaches in Oncology Foster the Need for an Appropriate Molecular Profiling Strategy

An Update from the European Society for
Medical Oncology (ESMO) Congress 2018

Speakers:	Luca Quagliata Clinical Sequencing and Oncology Division, Thermo Fisher Scientific, Waltham, Massachusetts, USA
Disclosure:	Luca Quagliata is an employee of Thermo Fisher Scientific. He has declared no further conflicts of interest.
Acknowledgements:	Dr Quagliata collected this information at the ESMO Congress 2018 and acknowledges the support of Thermo Fisher Scientific Clinical Sequencing Division Team during the event.
Support:	The writing and publication of this article were supported by Thermo Fisher Scientific.
Citation:	EMJ Oncol. 2018;6[1]:42-48.

Meeting Summary

Adding a molecular perspective to the traditional multidisciplinary management of cancer patients is substantially hampering the adoption of precision therapy. Indeed, at this year's European Society for Medical Oncology (ESMO) Congress in Munich, Germany, gathering >28,000 healthcare professionals spanning a range of disciplines, fields, and stakeholder groups, and >500 invited speakers, much attention focussed on discussing how to facilitate the integration of molecular data in the clinical management of cancer patients.

INTRODUCTION

A number of novel treatment options, either in the form of new agents or updated therapeutic strategies, with sequential drug exposure and dosage adjustments, were presented and debated during the event. Furthermore, along with the novelties in the drug space, the scene was equally occupied by the companion diagnostic compartment, with a substantial number of dedicated workshops, satellite events, and new product launches. Three critical factors have emerged as necessary for any meaningful

molecular diagnostic approach to impact patient outcomes through clinical actionability.

Tumour Tissue Requirements

The need for minimal tissue sample starting material should be a basic requirement for any test to be broadly introduced into routine clinical practice. Low input means, for example, being able to assess genomic variants from small needle biopsy and cytological specimens. This is commonly used for non-small cell lung carcinoma (NSCLC) diagnosis and will eventually lead to more patients with actionable results.

Testing Turnaround Times

Complete biomarker results should be available within days rather than weeks. Indeed, many European institutions have started to build in-house sequencing facilities to reduce the time to obtain final results; this allows clinicians to start treating patients more quickly, aiming to achieve diagnosis and treatment initiation within days (Figure 1). Conversely, also hampered by logistical issues, the institutions that outsource tests can take weeks to deliver data,^{1,2} a timeframe that is no longer acceptable, especially in cases such as late-stage NSCLC. In addition, when the number of samples to be tested reaches substantial proportions, the outsourcing testing strategy can result in

increased pressure on the healthcare system due to third-party margins along with shipment fees, leading to higher overall costs regardless of the payer.³

Adequate Biomarker Coverage

Testing should include updated relevant biomarkers based on current knowledge and ongoing late-phase clinical trials. In fact, while offering a single, very large panel testing for hundreds of genes, of which many currently hold limited or no clinical actionability, biomarkers covering a plethora of genomic variants for many cancer types might be a very attractive research-oriented solution; a dedicated test covering clinically relevant genes is a more pragmatic and cost-effective approach.




Figure 1: In-house testing and its associated benefits.

A model to fit molecular tumour boards and foster local interactions among healthcare professionals, generating and retaining both knowledge and precious data.

Furthermore, in 46–80% of patient cases, the starting material is too minimal for large panel analysis.^{2,4} In some cases, this testing approach may require a rebiopsy, which comes with associated risks, elevated costs, and treatment delays or, when not applicable, can lead to suboptimal therapy selection.

While in the early years of biomarker testing outsourcing was a logical choice due to technical and investment constraints, nowadays outsourcing is largely reduced due to the fast development of sequencing technologies and the dramatic reduction in the cost of in-house biomarker testing. Therefore, sending to third-party labs is now a non-sustainable long-term approach.

Finally, given that precision oncology is a medical practice deployed at the local level, at the patient's bedside, and mostly via interactions between local healthcare professionals, in-house molecular profiling is the best fit to this model. In many of the ESMO-hosted discussions, it was clear that the flexibility to triage patient samples and to discuss in depth the findings at local tumour boards is key to providing optimal, truly personalised care.

NOVEL OPPORTUNITIES FOR LUNG TUMOUR TREATMENT AND TESTING

Targeted agents, such as the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib, erlotinib, afatinib, and osimertinib, have considerably transformed the management of patients with EGFR-mutated NSCLC, representing one of the most significant advances in lung tumour treatment for decades. The introduction of these agents into clinical practice has been developed along with the advances made in the molecular pathology field and the broad adoption of next-generation sequencing (NGS), allowing a robust and sensitive evaluation of EGFR status.

Furthermore, the recent success of immunotherapy in the metastatic NSCLC setting (independent from the EGFR status) has revolutionised the entire treatment scenario. Nonetheless, >50% of treated patients show no clear evidence of responding to immune checkpoint-blocking (ICB) therapies, underlining the need to develop new, robust predictive

biomarkers that should appropriately guide the selection of ICB agents.⁵ Programmed death-ligand 1 (PD-L1) expression, assessed by immunohistochemistry (IHC), has emerged as a predictive marker for the use of ICB agents in NSCLC.⁶ However, despite currently being the most commonly used biomarker in the immune oncology space, the analysis of PD-L1 by IHC comes with several significant challenges, including variability in preanalytical conditions, the use of different antibodies along with different staining platforms, the lack of an unequivocal type of scoring system, the typical IHC interobserver variability, and the issue of intrinsic tumour heterogeneity.^{5,6} Additionally, it is currently acknowledged that some patients with low or no PD-L1 expression may still benefit from checkpoint inhibition. Recently, the tumour cell mutational burden (TMB) status has been correlated with distinct degrees of clinical benefits in ICB-treated patients with various tumour types, including NSCLC.⁶ High mutational load/burden is commonly defined as ≥ 100 non-synonymous single nucleotide variants per genome as identified via whole-exome sequencing;⁷ however, this threshold can greatly vary between tumour types.⁷ Thus, major challenges remain to improve the robustness of TMB and eventually introduce it into routine diagnostics. Among these challenges, the definition of the optimal tumour purity, the minimal sequencing depth, and the need to identify an appropriate threshold for defining high and low mutational burden for different tumour types are key.^{5,7} In summary, while PD-L1 expression and TMB value may aid the identification of ICB responders, they identify distinct subclasses of patients and are not a clear dichotomous set of biomarkers.⁸⁻¹⁰ Outcomes from ESMO 2018 highlighted the need to further expand our understanding behind response to ICB, for example, focussing on the activity of tumour-infiltrating T cells through T cell receptor characterisation via sequencing.

Hampered by compelling evidence in the metastatic setting, accumulating data from preclinical investigations and retrospective studies of human lung cancer samples have been discussed, suggesting the presence of an immunosuppressive microenvironment in the early stage of the disease. This serves as another

indicator of the importance of investigating the role of T cells via repertoire analysis and an important reason to thoroughly investigate the role of T cells and T cell receptors. In fact, immunotherapy is now also studied in non-metastatic NSCLC.¹¹ Trials of checkpoint inhibitors have recently been completed (or are currently ongoing) in early-stage resectable NSCLC in different settings (neoadjuvant, combined neoadjuvant, and adjuvant therapy) and in various combinations with standard of care modalities. For example, very encouraging results have been reported in the PACIFIC trial,¹² wherein progression-free survival (PFS) was significantly longer with durvalumab versus placebo after chemoradiotherapy in Stage III NSCLC. This is an important development for immunotherapy, given that 30–60% of patients with Stage I–III NSCLC will ultimately develop post-resection metastases.¹¹

Another important option for lung cancer treatment, largely discussed at this year's ESMO Congress, relies on agents targeting genomic fusion products. For instance, ALK and ROS1 rearrangements define an important molecular subgroup (3–5% of cases) in advanced NSCLC, with major clinical implications. Now that alectinib has replaced the first-in-class ALK/ROS1/MET inhibitor (crizotinib) as the standard first-line therapy for ALK-positive advanced NSCLC,¹³ it is becoming clear that, after initial response to treatment, resistance develops and patients invariably progress. While other potent ALK inhibitors and brain-penetrable compounds have been approved, including brigatinib, ceritinib, and lorlatinib, questions remain concerning the optimisation of treatment sequencing strategies to prevent or reduce resistance. To this end, performing highly sensitive molecular profiling, allowing the detection of new rising genomic alterations and eventually impairing clinical response, will support the development of these novel treatment schemes.

Furthermore, tyrosine receptor kinase (TRK) fusion agents took to the stage at this year's ESMO Congress. A genomic rearrangement known as TRK fusion occurs when a member of the neurotrophic tyrosine receptor kinase (*NTRK*) gene family fuses with another unrelated gene, producing an altered tropomyosin receptor kinase (Trk) protein.¹⁴ This novel

protein product is permanently activated (i.e., uncontrolled kinase function), triggering a constant oncogenic signal cascade, which becomes the primary driver of tumour cell growth in patients with TRK fusion-positive cancer. *NTRK1/2/3* gene fusions occur in various adult and paediatric solid tumours with varying prevalence, including appendiceal cancer, cholangiocarcinoma, colorectal cancer, gastrointestinal stromal tumours, infantile fibrosarcoma, lung cancer, mammary analogue secretory carcinoma of the salivary gland, melanoma, pancreatic cancer, thyroid cancer, and various sarcomas.¹⁵ Only sensitive and specific tests can reliably detect TRK fusion-positive events. The ESMO Precision Medicine Working Group has released specific suggestions¹⁶ that recommend RNA-based NGS testing as the preferred method to investigate genomic alterations such as gene fusions. Fluorescence *in situ* hybridisation can also be used to test for TRK fusion cancer, while IHC can detect the presence of the Trk protein. However, both approaches substantially lack sensitivity and specificity, thus leading to suboptimal patient selection.

Among the presented new agents, entrectinib is a central nervous system-active potent inhibitor of all Trk proteins, as well as ROS1 and ALK.¹⁷ Prof Demetri, Boston, Massachusetts, USA, presented an integrated efficacy and safety analysis from three Phase I/II clinical trials using entrectinib: ALKA,¹⁸ STARTRK-1,¹⁹ and STARTRK-2.²⁰ Data show that treatment with entrectinib induced responses that were durable in >50% of treated patients. Notably, entrectinib is well tolerated with limited side effects and induces clinically meaningful systemic responses across tumours with a variety of histologies and in patients with and without central nervous system disease. This represents an advance in precision medicine, with entrectinib offering benefits for *NTRK*-fusion-positive patients as a tumour agnostic targeted therapy. Based on these results, screening patients for *NTRK* gene fusions in solid tumours should be actively considered.

NEW OPPORTUNITIES IN OVARIAN AND BREAST CANCERS: THE NEED FOR *BRCA* TESTING

During the ESMO Congress, the first Phase III study of a poly (ADP-ribose) polymerase inhibitor as maintenance therapy after first-line chemotherapy for ovarian cancer positive findings were reported. In the SOLO1 trial²¹ of olaparib in patients with *BRCA*-mutated advanced ovarian cancer, the primary endpoint (investigator-assessed PFS) was successfully met, with a statistically significant and clinically meaningful improvement compared to placebo. At a median follow-up of 41 months, maintenance olaparib reduced the risk of disease progression or death by 70% compared to placebo. These unmatched findings were reinforced by a significant improvement in median time to first subsequent therapy or death (51.8 months for olaparib versus 15.1 months for placebo). Notably, adverse events were mostly low grade, while health-related quality of life scores did not change from baseline following olaparib exposure. These data suggest that poly (ADP-ribose) polymerase inhibitors may have an earlier entry point in the treatment of ovarian cancer and underline the importance of determining *BRCA* status at diagnosis by sequencing. Dr Curigliano, Milan, Italy, commented on SOLAR-1 trial data. SOLAR-1²² demonstrated a significant PFS benefit with the phosphatidylinositol-3-kinase (PI3K) inhibitor, alpelisib, plus hormone therapy, fulvestrant, compared with placebo plus fulvestrant in patients with PI3K-mutated cancer. This study also highlighted the value of determining yet another genomic biomarker status (i.e., PI3K mutations) at diagnosis by sequencing to accurately select the treating agent. Finally, robust data from a large patient population study indicate for the first time that immunotherapy could be an effective first-line option for patients with metastatic triple-negative breast cancer. Additional studies will now be conducted to reinforce these preliminary findings.

LIQUID BIOPSY FOR ROUTINE TESTING: HYPES AND HOPES

Supported by the aforementioned examples and with the advent of targeted therapies,

molecular profiling is often needed to guide therapeutic decisions, both at diagnosis and following the development of resistance, resulting in multiple tissue biopsies during the disease course. However, intratumour heterogeneity and clonal evolution due to prior lines of therapies further foster the complexity of the treatment decision, representing a truly challenging task for current therapeutic approaches.²³ Dr Besse, Villejuif, France, in multiple appearances during the ESMO Congress, emphasised that while the gold standard method for molecular profiling involves the examination of DNA/RNA extracted from a tissue biopsy, some clear drawbacks are associated with this approach. For instance, the lack of feasibility in some cases due to the anatomical position of the tumour mass, the invasiveness of the procedure, and the possible acquisition of insufficient tissue all lead to suboptimal overall testing quality of gene sequencing.²⁴ In the oncology community, interest is growing in the use of less invasive and costly approaches, such as liquid biopsy, analysing circulating tumour DNA (ctDNA) released into plasma from cancer cells during apoptosis or necrosis.²⁵

Nowadays, ctDNA tests are used primarily for patients when tissue samples are not available, or to guide targeted therapy in specific clinical situations (e.g., resistance after tyrosine kinase inhibitor treatment). Dr Dienstmann, Barcelona, Spain, commented that during a study of patients receiving osimertinib, MET amplification (15%) and EGFR Cys797Ser mutation (7%) were the most common resistance mechanisms, with no evidence of an acquired EGFR Thr790Met mutation. Conversely, the incidence of Thr790Met mutation in the standard-of-care arm was found in about 47% of cases. These findings underline the need to sequence ctDNA with a multiplex gene panel-based approach rather than with a single gene testing approach (i.e., only looking for Thr790Met).²⁶

In addition, much hope is pinned on the further development of liquid biopsy applications, for example, detecting minimal residual disease or risk of relapse in early stages, a path that is actively explored in several ongoing studies.²⁷ For example, Dr Bonanno, Padova, Italy, presented interim findings from the MAGIC-1

trial²⁸ suggesting that changes in plasma levels of a *KRAS* mutation significantly correlated with the radiological assessment of disease progression in patients with advanced NSCLC receiving either chemotherapy or immunotherapy. Moreover, the data also suggest that, in patients receiving immunotherapy, early reduction of the mutated allele abundance in plasma may predict favourable outcomes.

CALLING ON MOLECULAR DIAGNOSTICS

Given the rapidly increasing amount of genomic information available, thanks to the reduction in sequencing cost and the democratisation of molecular profiling, clinicians are now confronted with the need to prioritise driver over passenger genomic alterations and choose the most appropriate treatment when multiple targetable alterations are found.

During the ESMO Congress 2018, key opinion leaders from across the globe highlighted that molecular tumour boards, a new form of interaction for medical professionals, are rapidly diffusing into major cancer reference centres.²³ The main goal for a molecular tumour board is to match the unique genetic profile of a patient's cancer with a drug (or combination therapy) having the highest evidence of clinical actionability, or to explore the possibility of enrolling patients into a recruiting clinical trial. Dr Curioni, Zurich, Switzerland, part of the ESMO press committee, highlighted that lung cancer is an extraordinary example that demonstrates the value of multidisciplinary discussion of molecular tumour profiling data, which has resulted in a dramatic improvement in the prognosis of cancer patients harbouring driver genetic alterations in genes like *ALK*, *ROS1*, *EGFR*, *cMET*, *BRAF*, and *NTRK*.²⁹ Prof André, Villejuif, France, highlighted the first ESMO scale to rank and prioritise genomic alterations: ESMO scale for clinical actionability of molecular targets (ESCAT). ESCAT aims to improve the interpretation of sequencing results and link them to appropriate clinical trials. Furthermore, the ESMO Precision Medicine Working Group released updated recommendations concerning sequencing practice, including detection of TRK fusions, microsatellite instability, and a general guide

on how to handle genetic variants detected by NGS. Also highlighted was the unmet need to integrate multiple layers of data from curated available sources (National Cancer Institute [NCI], The Cancer Genome Atlas [TCGA], ESMO-OncologyPro, and ESCAT) and present them in an intuitive and accessible manner while still accurately offering a complete picture of an individual's medical profile in the form of a clinical decision support tool. This represents the next challenge for companies serving cancer-treating clinicians. The key to success for such a tool is a simple and direct workflow of guided steps for clinicians to navigate the magnitude of molecular information, enabling decisions to be made as quickly and reliably as possible. Moving in this direction, the ESMO Magnitude of Clinical Benefits scale (ESMO-MCBS) is a tool designed to assess the clinical benefit of different cancer medications, allowing stakeholders to discriminate between high-value treatments (i.e., improving survival and/or quality of life of cancer patients, from modest to marginal approaches). At this year's ESMO Congress, a set of workshops aimed to address how to prepare the next generation of the ESMO-MCBS for the integration of molecular diagnostics-related benefits in the cost calculation process.³⁰ Given that diagnostics-related reimbursement policies across the European Union (EU), the USA, and the Asia-Pacific region will likely evolve in the near future, much attention will be paid to this topic at next year's Congress.

Overall, the ESMO Congress highlighted that in order to make precision medicine the global standard of care, including the wide application of genome-analysis in the form of a feasible diagnostic solution, and not only as a privileged option for a few national healthcare systems, a variety of socioeconomic factors will need to be considered.³¹ Health policy makers, medical institutions, manufacturers, clinicians, and biomedical researchers, along with patient associations, will have to engage in this process through global initiatives, while being able to deploy them at the local level.³²

CONCLUSION

To conclude, the list of new therapies associated with specific biomarkers is growing steadily.

What was once a vision for improved cancer care is now a reality, with molecular insights resulting in better patient management, reduced treatment side effects, and enhanced quality of life. At this year's ESMO Congress, most

key opinion leaders clearly pointed out that investments in high-quality molecular profiling for tumour patients will undoubtedly have an impact on appropriate treatment decisions and, thus, eventually impact clinical outcomes.

References

1. Yu TM et al. Multiple biomarker testing tissue consumption and completion rates with single-gene tests and investigational use of oncoprint dx target test for advanced non-small-cell lung cancer: A single-center analysis. *Clin Lung Cancer*. 2018;pii: S1525-7304(18)30204-3.
2. Miller TE et al. Clinical utility of reflex testing using focused next generation sequencing for management of patients with advanced lung adenocarcinoma. *J Clin Pathol*. 2018. [Epub ahead of print].
3. Hamblin A et al. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service. *PLoS Medicine*. 2017;14(2):e1002230.
4. Prager GW et al. Global cancer control: Responding to the growing burden, rising costs and inequalities in access. *ESMO Open*. 2018;3(2):e000285.
5. Topalian SL et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. *Nat Rev Cancer*. 2016;16(5):275-87.
6. Frampton GM et al. Assessment and comparison of tumor mutational burden and microsatellite instability status in >40,000 cancer genomes. *Ann Oncol*. 2016;27(6 suppl 1):520.
7. Rizvi NA et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*. 2015;348(6230):124-8.
8. Ma W et al. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. *J Hematol Oncol*. 2016;9(1):47.
9. Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *New Eng J Med*. 2012;366:2443-54.
10. Garon EB et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *New Eng J Med*. 2015;372(21):2018-28.
11. Forde PM et al. Neoadjuvant PD-1 blockade in resectable lung cancer. *New Eng J Med*. 2018;378(21):1976-86.
12. AstraZeneca. A global study to assess the effects of MEDI4736 following concurrent chemoradiation in patients with Stage III unresectable non-small cell lung cancer (PACIFIC). NCT02125461. <https://clinicaltrials.gov/ct2/show/NCT02125461>.
13. Peters S et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. *New Eng J Med*. 2017;377(9):829-38.
14. Kumar-Sinha C et al. Landscape of gene fusions in epithelial cancers: Seq and ye shall find. *Genome Med*. 2015;7:129.
15. Amatu A et al. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. *ESMO Open*. 2016;1(2):e000023
16. Reis-Filho J. Detecting MSI and TRK fusion using NGS: ESMO recommendations. ESMO 2018 Congress, 19th-23rd October, 2018.
17. Drilon A et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). *Cancer Discov*. 2017;7(4):400-9.
18. Demetri G. Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive (NTRK-fp) Tumors: Pooled Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. ESMO 2018 Congress, 19th - 23rd October, 2018.
19. Hoffmann-La Roche. study of oral RXDX-101 in adult patients with locally advanced or metastatic cancer targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alterations. (STARTRK-1). NCT02097810. <https://clinicaltrials.gov/ct2/show/NCT02097810>.
20. Hoffmann-La Roche. Basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK gene rearrangements (Fusions) (STARTRK-2). NCT02568267. <https://clinicaltrials.gov/ct2/show/NCT02568267>.
21. AstraZeneca. Olaparib maintenance monotherapy in patients with BRCA mutated ovarian cancer following first line platinum based chemotherapy. (SOLO-1). NCT01844986. <https://clinicaltrials.gov/ct2/show/NCT01844986>.
22. Novartis Pharmaceuticals. Study assessing the efficacy and safety of alpelisib plus fulvestrant in men and postmenopausal women with advanced breast cancer which progressed on or after aromatase inhibitor treatment. (SOLAR-1). NCT02437318. <https://clinicaltrials.gov/ct2/show/NCT02437318>.
23. Tannock IF, Hickman JA. Limits to personalized cancer medicine. *New Eng J Med*. 2016;375(13):1289-94.
24. Karachaliou N et al. Real-time liquid biopsies become a reality in cancer treatment. *Ann Transl Med*. 2015;3(3):36.
25. Bernabé R et al. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer? *Eur J Cancer*. 2017;81:66-73.
26. Tang ZH, Lu JJ. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies. *Cancer Lett*. 2018;420:242-6.
27. Cheung AH et al. Latest development of liquid biopsy. *J Thorac Dis*. 2018;10(Suppl 14):S1645-51.
28. Bonanno L et al. Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study. *Ann Oncol*. 2018;29(Suppl 8).
29. Curioni Fontecedro A. Harnessing the power of big data to optimise cancer management. ESMO Daily Reporter, Saturday 20th October, P:10. Available at: <https://www.esmo.org/content/download/158452/2894554/file/ESMO-2018-Congress-Daily-Reporter-Saturday.pdf>. Last accessed: 22 November 2018.
30. Saluja R et al. Examining trends in cost and clinical benefit of novel anticancer drugs over time. *J Oncol Pract*. 2018;14(5):e280-94.
31. Remon J, Dienstmann R. Precision oncology: Separating the wheat from the chaff. *ESMO Open*. 2018;3(6).
32. Siew-Kee Low et al. Breast cancer: The translation of big genomic data to cancer precision medicine. *Cancer Sci*. 2018;109(3):497-506.